tradingkey.logo

Reviva Announces Regulatory Update Regarding The Development Of Brilaroxazine For The Treatment Of Schizophrenia

ReutersDec 23, 2025 1:19 PM

- Reviva Pharmaceuticals Holdings Inc RVPH.O:

  • REVIVA ANNOUNCES REGULATORY UPDATE REGARDING THE DEVELOPMENT OF BRILAROXAZINE FOR THE TREATMENT OF SCHIZOPHRENIA

  • REVIVA PHARMACEUTICALS HOLDINGS INC - FDA RECOMMENDS SECOND PHASE 3 TRIAL FOR BRILAROXAZINE

  • REVIVA PHARMACEUTICALS HOLDINGS INC - RECOVER-2 TRIAL PLANNED FOR H1 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Related Articles

Tradingkey
KeyAI